

Data table for Figure 10. Adults 18 years of age and over reporting prescription antidepressant and antianxiety drug use in the past month, by sex and age: United States, 1988–1994 and 2005–2008

Sex and age	Multum Lexicon Plus therapeutic drug class							
	Antidepressant drugs				Antianxiety drugs (anxiolytics, sedatives, and hypnotics)			
	1988–1994		2005–2008		1988–1994		2005–2008	
	Percent	SE	Percent	SE	Percent	SE	Percent	SE
Total								
18 years and over, age-adjusted	2.4	0.2	11.1	0.4	3.9	0.2	5.7	0.3
18 years and over, crude.	2.3	0.2	11.4	0.5	3.6	0.2	5.8	0.3
Men								
18 years and over.	1.5	0.2	6.2	0.4	2.6	0.3	4.3	0.4
18–44 years	*1.0	0.2	3.6	0.6	*1.0	0.2	2.1	0.4
45–64 years	*2.3	0.5	8.5	0.8	4.3	0.8	6.2	0.9
65 years and over	*2.3	0.5	10.0	0.9	6.1	0.9	7.1	0.9
Women								
18 years and over.	3.1	0.3	16.2	0.7	4.6	0.3	7.3	0.5
18–44 years	2.3	0.4	11.9	0.8	1.9	0.3	4.3	0.4
45–64 years	4.6	0.7	21.9	1.2	7.5	0.8	9.3	0.9
65 years and over	3.5	0.4	17.3	1.1	9.1	0.7	11.8	1.1

SE is standard error.

* Estimates are considered unreliable. Data preceded by an asterisk have a relative standard error of 20%–30%.

NOTES: The drug therapeutic class is based on Lexicon Plus, a proprietary database of Cerner Multum, Inc. Lexicon Plus is a comprehensive database of all prescription and some nonprescription drug products available in the U.S. drug market. In the National Health and Nutrition Examination Survey, data on prescription drug use only are collected. Up to four classes are assigned to drugs. All four classes were included in this analysis. Drugs classified into more than one class were counted in each class. For more information, see: http://www.cdc.gov/nchs/data/nhanes/frequency/rxq_drug.pdf. Estimates are age-adjusted to the year 2000 standard population using three age groups: 18–44 years, 45–64 years, and 65 years and over. See Appendix II, Age adjustment; Table 94.

SOURCE: CDC/NCHS, National Health and Nutrition Examination Survey.

References (continued from page 19)

- Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005;62(6):617–27.
- Timonen M, Liukkonen T. Management of depression in adults. *BMJ* 2008;336(7641):435–9.
- Stone KJ, Viera AJ, Parman CL. Off-label applications for SSRIs. *Am Fam Physician* 2003;68(3):498–504.
- Chouinard G. The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs. *J Psychiatry Neurosci* 2006;31(3):168–76.